Sponsor or institution

Clinical trials and research at Guangdong Hengrui Pharmaceutical Co., Ltd

• 19Clinical trials
• 1Country

Newest trials

All recruiting trials (19)

• Safety test of SHR-7590 in healthy adults and adults with moderate-to-severe inflammatory bowel disease

  This early human study tests whether SHR-7590 is safe and tolerable in healthy adults and in adults with moderate-to-severe inflammatory bowel disease.

  Recruiting Phase 1 Guangdong Hengrui Pharmaceutical Co., Ltd · Hangzhou, Zhejiang · NCT07758101

• A single-dose SHR-7012 safety study in healthy adults

  This study tests a single dose of SHR-7012 to see if it is safe and how it behaves in the body of healthy adults.

  Recruiting Phase 1 Guangdong Hengrui Pharmaceutical Co., Ltd · Hangzhou, Zhejiang · NCT07749651

• SHR-1139 injectable treatment for adults with plaque psoriasis

  This study tests whether an SHR-1139 injection works and is safe for adults with plaque psoriasis.

  Recruiting Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Guangzhou, Guangzhou · NCT07719530

• HRS-9821 Inhalation Suspension for COPD: Safety and Dose Finding in Adults

  This study tests whether HRS-9821 inhalation can be safely taken and help people with moderate to severe COPD, and aims to find a reasonable dose.

  Recruiting Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Shanghai, Shanghai Municipality · NCT07640451

• SHR-2173 injection added to standard care for generalized myasthenia gravis

  This Phase 2 trial tests whether SHR-2173 added to usual treatment helps adults with generalized myasthenia gravis more than a placebo add-on.

  Recruiting at 2 sites Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Changsha, Hunan and 1 other locations · NCT07622342

• HRS-9821 Inhaled Powder: Safety and How It Behaves in Healthy People and COPD Patients

  This early-phase study tests whether inhaled HRS-9821 powder is safe and tolerable in healthy adults and in people with COPD, while also looking at how the drug moves through and affects the body after a single dose in healthy volunteers and multiple doses in COPD patients.

  Recruiting Phase 1 Guangdong Hengrui Pharmaceutical Co., Ltd · Chengdu, Sichuan · NCT07567872

• SHR-2173 for people with primary IgA nephropathy

  This trial will test whether SHR-2173 injections can reduce proteinuria and protect kidney function in adults with primary IgA nephropathy compared with placebo over 48 weeks.

  Recruiting at 2 sites Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Guangzhou, Guangdong and 1 other locations · NCT07354932

• SHR-1819 injections for adolescents with moderate-to-severe atopic dermatitis

  This Phase 3 trial will test whether SHR-1819 injections can reduce symptoms in adolescents aged 12–17 with moderate-to-severe atopic dermatitis.

  Recruiting at 2 sites Phase 3 Guangdong Hengrui Pharmaceutical Co., Ltd · Shenyang, Liaoning and 1 other locations · NCT07309055

• SHR-2173 for adults with systemic lupus erythematosus

  This trial will try an injectable drug called SHR-2173 to help adults with active systemic lupus erythematosus.

  Recruiting at 2 sites Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Beijing, Beijing Municipality and 1 other locations · NCT07299422

• SHR-2173 injections for adults with primary membranous nephropathy

  This Phase II test will try SHR-2173 injections in adults (18–75) with biopsy-proven primary membranous nephropathy to see if they are safe, reduce disease activity, and to measure how the drug acts in the body.

  Recruiting Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Nanjing, Jiangsu · NCT07289763

• SHR-2173 injection for adults with active lupus nephritis

  This Phase II trial will test whether SHR-2173 injections help adults with active lupus nephritis improve kidney inflammation and function compared with placebo.

  Recruiting Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Nanjing, Jiangsu · NCT07229742

• SHR-1905 treatment for moderate-to-severe atopic dermatitis

  This trial will test whether SHR-1905 injections help adults aged 18–75 who have moderate-to-severe atopic dermatitis.

  Recruiting Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Guangzhou, Guangdong · NCT07211542

• SHR-2173 injections for adults with primary immune thrombocytopenia.

  This will test whether multiple subcutaneous injections of SHR-2173 are safe and well tolerated in adults with primary immune thrombocytopenia and low platelet counts.

  Recruiting Phase 1 Guangdong Hengrui Pharmaceutical Co., Ltd · Wuhan, Hubei · NCT07206758

• HRS-9813 for idiopathic and progressive pulmonary fibrosis

  This trial will test whether HRS-9813 capsules help adults with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF) slow disease progression or preserve lung function.

  Recruiting Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Beijing, Beijing Municipality · NCT07192939

• SHR-1905 injection for chronic rhinosinusitis with nasal polyps

  This trial will test whether SHR-1905 injections help adults with chronic rhinosinusitis with nasal polyps reduce polyp size and symptoms compared with placebo.

  Recruiting Phase 3 Guangdong Hengrui Pharmaceutical Co., Ltd · Shanghai, Shanghai Municipality · NCT07132827

• SHR-1905 for adults with severe uncontrolled asthma

  This Phase 3 trial will test whether SHR-1905 injections help adults with severe uncontrolled asthma have fewer flare-ups and better symptom control.

  Recruiting Phase 3 Guangdong Hengrui Pharmaceutical Co., Ltd · Guangzhou, Guangdong · NCT07098403

• Evaluating SHR-1819 injection for treating Prurigo Nodularis in adults

  This study is testing if an injection called SHR-1819 can help adults with Prurigo Nodularis feel better compared to a placebo.

  Recruiting Phase 2/3 Guangdong Hengrui Pharmaceutical Co., Ltd · Beijing, Beijing Municipality · NCT06554509

• Long-term safety and benefits of SHR-1703 for adults with eosinophilic asthma

  This research will test whether regular SHR-1703 injections are safe over the long term and help control symptoms in adults with eosinophilic asthma who remain symptomatic despite medium- to high-dose inhaled steroids.

  Recruiting Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Chengdu, Sichuan · NCT06441812

• Evaluating SHR-1703 for Eosinophilic Granulomatosis With Polyangiitis

  This study is testing a new treatment called SHR-1703 to see if it can help adults with Eosinophilic Granulomatosis With Polyangiitis feel better and manage their symptoms.

  Recruiting at 2 sites Phase 2/3 Guangdong Hengrui Pharmaceutical Co., Ltd · Beijing, Beijing Municipality and 1 other locations · NCT05979051

Quick answers

How many clinical trials run by Guangdong Hengrui Pharmaceutical Co., Ltd are recruiting right now?

19, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 10, Phase 1: 4, Phase 3: 3, Phase 2/3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →